New $25 Million Accelerator Bets On Better Model For Rare Disease
Greg Licholai MD, Contributor
Fri, 14 August 2026 at 12:01 am GMT+5:30
6 min read
A new Pittsburgh-based initiative is making a $25 million bet on a persistent problem in medicine: promising rare disease science too often fails to become a treatment
The Richard King Mellon Foundation has committed up to $25 million over three years to launch Rare Ventures, a venture philanthropy platform led by the EB Research Partnership (EBRP). The initiative brings together the University of Pittsburgh Health Sciences, UPMC Children’s Hospital of Pittsburgh, the UPMC Vision Institute, Carnegie Mellon University, Stanford Medicine and ElevateBio. Its ambition is broader than funding research grants. Rare Ventures intends to connect patient data, artificial intelligence, translational science, clinical development, manufacturing and commercialization in one coordinated system.
Michael Hund, EBRP’s CEO and co-founder of Rare Ventures explained the urgency, “Rare disease patients have waited long enough.”
Rare diseases often do not suffer from a shortage of determined families or scientific ideas. However, the current fragmented development model favors work on conditions with bigger patient populations, deeper datasets and more predictable commercial returns
Rare Diseases Are Collectively Common
In the United States, a rare disease is defined as affecting fewer than 200,000 people. Yet they are not rare when considered together. The FDA estimates that more than 10,000 rare diseases affect over 30 million Americans, roughly one in ten people, and about half of those patients are children
Global estimates vary because countries use different definitions and many patients remain undiagnosed. A widely cited analysis of Orphanet data estimated that rare diseases affect 3.5% to 5.9% of the world’s population, or roughly 263 million to 446 million people using the study’s population base
The treatment gap is even more striking. The National Institutes of Health has estimated that about 95% of rare diseases lack an FDA-approved treatment. This is thousands of separate unmet needs divided among small patient populations, few specialists and incomplete natural-history data
Investment Goals
Rare Ventures will initially work across seven conditions, with epidermolysis bullosa, PACS1 syndrome and LMNB1-related adult-onset autosomal dominant leukodystrophy among those publicly identified. Partners bring complementary capabilities: clinical expertise and patient access, AI and computational biology, translational research, gene and cell therapy development, and advanced manufacturing
